Pediatric practices that began recommending HPV vaccination at ages 9 or 10 achieved higher series completion by age 13 than practices that continued recommending it at ages 11 or 12, with children completing the series about a year earlier, according to an abstract of a cluster-randomized trial presented at IDWeek 2026.
“What our data show is that the age at which families first hear the recommendation changes how many children are protected and how soon,” said presenting author Sean T. O’Leary, MD, MPH, of the University of Colorado School of Medicine and Children’s Hospital Colorado in Aurora.
Most U.S. practices introduce HPV vaccine at age 11 or older. Dr. O’Leary said earlier observational studies suggested that starting at ages 9 or 10 helped children complete the series on time but could not establish whether earlier vaccination caused the improvement or reflected differences among clinicians or families.
The trial, conducted from 2021 to 2026, enrolled 31 pediatric practices in Colorado and California and covered more than 62,000 children and adolescents. All participating practices recommended starting vaccination at ages 11 or 12 before randomization. Researchers assigned 16 practices with 106 clinicians to recommend starting at ages 9 or 10, while 15 practices with 112 clinicians continued recommending initiation at ages 11 or 12. The study assessed median age at series initiation and completion, as well as initiation and completion rates by age 13. Analyses accounted for clustering within practices.
Clinicians in both groups received online training on recommending HPV vaccination and practice-based strategies to increase uptake, along with annual booster training and reviews of practice-level vaccination data. The earlier-start group also received guidance on discussing vaccination at younger ages with parents.
The trial found that by age 13, 77.1% of children in earlier-start practices had initiated the series and 61.6% had completed it, compared with 67% and 45.1%, respectively, in comparison practices.
Median age at series completion was 12.2 years in earlier-start practices vs 13.3 years in comparison practices. Median age at series initiation was 11 years vs 11.8 years, respectively.
Researchers also examined whether early HPV vaccination affected other care. Well-child visits at ages 11 or 12 did not differ between study groups, nor did receipt of meningococcal or tetanus, diphtheria and acellular pertussis vaccines by age 13.
Clinician surveys conducted every six months for up to four years, along with interviews with clinicians and parents, assessed implementation and family responses. Dr. O’Leary said nearly all clinicians assigned to earlier initiation switched within a month or two. Parental concerns, hesitancy and acceptance appeared similar between groups.
Dr. O’Leary suggested that clinicians who currently begin recommending HPV vaccination at age 11 or older consider earlier introduction. “We would also suggest that policymakers consider a preferential recommendation for starting at ages 9 or 10, rather than simply permitting it,” he said.
All authors listed in the abstract reported no financial relationships to disclose.